Plain-English translation of NCT06649123 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Colorectal Cancer research guide →Researchers are testing a new way to analyze rectal mucus called the OriCol multiomics assay to see if it can accurately identify colon cancer and high-risk polyps. The test looks for genetic and microbial signatures—essentially biological fingerprints—in a mucus sample that may signal cancer or dangerous polyps. This study will help determine whether this simple test could become a useful tool for diagnosing colon cancer.
Currently, people suspected of having colon cancer must wait for a colonoscopy to get a diagnosis, which takes time and resources. This trial aims to see if analyzing rectal mucus could provide faster, earlier detection to help catch cancer and dangerous polyps sooner.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will provide a rectal mucus sample using a simple collection device, typically during your initial urgent cancer evaluation visit. Your sample will then be analyzed using the new multiomics test to look for cancer and polyp markers. The study will compare the results of this test with your colonoscopy findings to see how accurate it is.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
United Kingdom
Collaborators
Shrewsbury and Telford Hospitals NHS Trust
Enrollment target
~6,600 participants
Started
November 2024
Primary completion
April 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 99 Years
Last updated on clinicaltrials.gov in April 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Jon Lacy-Colson, FRCS
Origin Sciences
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.